Release Date: Friday, December 11, 2020     Expiration Date: Saturday, December 11, 2021

      Pre-Activity Self-Assessment:


Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) continue to be associated with poor clinical outcomes despite continued advances in prevention and management. For critically ill patients, long-term outcomes are especially poor with high rates of in-hospital and 30-day mortality. Further complicating management decisions has been the emergence of the COVID-19 pandemic. Emerging data is demonstrating that up to a third of COVID-19 patients have a secondary infection, with bacterial superinfection or coinfection more likely in patients with severe illness. ICU COVID-19 patients with prolonged hospitalization and/or intubation are also at greater risk of infection with multidrug-resistant (MDR) Gram-negative bacteria, likely reflecting hospital-acquired infection. Patient outcomes are closely linked to timely and appropriate initial therapy. Evidence-based strategies have been identified to help improve long-term outcomes of HABP/VABP patients. These include the use of antibiograms, rapid diagnostics, and newer antimicrobials. Maximizing the potential of these tools requires ID clinicians to be fully competent on their use in clinical practice in order to tailor management approaches based on patient factors and needs. This program is designed to build competence, confidence, and skills in the management of HABP/VABP while increasing the understanding of how to utilize the latest tools as part of antimicrobial stewardship efforts.



At the conclusion of the educational activity, the learner should be able to:

  • Describe the evolving epidemiology and resistance mechanisms of Gram-negative pathogens that commonly cause hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)
  • Implement the latest evidence-based diagnostic and therapeutic approaches when managing patients with HABP/VABP caused by multidrug-resistant (MDR) Gram-negative bacteria
  • Differentiate the pharmacology and antibacterial activity of newer antimicrobial agents targeting MDR Gram-negative bacteria
  • Evaluate strategies to guide antimicrobial selection and pathogen-specific therapy to optimize clinical and economic outcomes of patients with HABP/VABP



This continuing medical education activity meets the needs of healthcare providers in a variety of practice settings, including large and small health systems, outpatient clinics, managed-care organizations, long-term care facilities, and academia. This activity would be especially beneficial for ID physicians and pharmacists who are on the frontline of managing patients with serious bacterial infections.



Keith A. Rodvold, PharmD, FCCP, FIDSA
UIC Distinguished Professor
Co-Director, Section of Infectious Diseases Pharmacotherapy
Colleges of Pharmacy and Medicine
University of Illinois at Chicago
Chicago, IL

Edward Septimus, MD, FIDSA, FACP, FSHEA
Senior Lecturer
Therapeutics Research and Infectious Disease Epidemiology
Department of Population Medicine
Harvard Medical School & Harvard Pilgrim Health Care Institute
Adjunct Professor, Internal Medicine
Texas A&M College of Medicine
Houston, TX

George H. Karam, MD, MACP
Paula Garvey Manship Chair of Medicine
Department of Medicine
Louisiana State University School of Medicine in New Orleans
Baton Rouge Branch Campus
Baton Rouge, LA

Marin Kollef, MD, FACP, FCCP
Professor of Medicine
Virginia E. and Sam J. Golman Chair in
Respiratory Intensive Care Medicine
Washington University School of Medicine
Director, Critical Care Research
Director, Respiratory Care Services
Barnes-Jewish Hospital
St. Louis, MO

Melissa D. Johnson, PharmD, MHS
Associate Professor of Medicine
Division of Infectious Diseases & International Health
Duke University Medical Center
Liaison Clinical Pharmacist
Duke Antimicrobial Stewardship Outreach Network (DASON)
Durham, NC




This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Center for Independent Healthcare Education (Center) and Vemco MedEd. Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Center designates this Enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts AMA PRA Category 1 Credit™ for the PRA from organizations accredited by ACCME.

Nurse Practitioners
Nurse Practitioners will receive certificate of AMA PRA Category 1 Credit™ as this is an ACCME accredited program and its accreditation is recognized by Nurse Practitioner boards.

AccreditationCenter for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center has assigned 2.0 contact hours (0.2 CEUs) of continuing pharmacy education credits for participating in this activity.
ACPE UAN: 0473-9999-20-010-H01-P
Activity type: Application-based

For questions regarding the accreditation of this activity, please contact us at


Method of Participation and Instruction for Credit

  1. Review the entire CME/CPE information including target audience, learning objectives, and disclosures.
  2. Review the activity in its entirety.
  3. Complete the Online Post Test, Evaluation, and Credit Application form
  4. Please note that to receive credit you must achieve a score of at least 75%.
  5. Pharmacists: The information that you participated will be uploaded to CPEMonitor and you will be able to access your credits from the profile you set up with NABP.
  6. Physicians: Certificate of Credit will be emailed to you within 4 weeks.


Disclosure of Conflicts of Interest

In accordance with policies set forth by the Accreditation Council for Continuing Medical Education (ACCME), Center for Independent Healthcare Education requires all faculty members and spouses/significant others with an opportunity to affect the content of a continuing education activity to disclose any relevant financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling or distributing health care goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activity.

Relevant relationships include roles such as speaker, author, consultant, independent contractor (including research), employee, investor, advisory committee member, board member, review panelist, and investigator. If a potential speaker or author indicates a possible conflict of interest, the conflict will be resolved by choosing another speaker or author for that topical area, or the slides, handouts, and/or monograph will be reviewed and approved by a qualified commercially-disinterested peer.

Keith Rodvold, PharmD has relevant financial relationships with the following commercial interests:

  • Advisory Board: Entasis Therapeutics, Shionogi Inc., Qpex Biopharma
  • Consultant: BLC USA LP, Chimerix Inc., Debiopharm International, Janssen Pharmaceuticals, Qpex Biopharma, Shionogi Inc., Spero Therapeutics, VenatoRx
  • Speaker’s Bureau: Merck & Co., Inc., Shionogi Inc.
  • Dr. Rodvold does not discuss off-label uses of any products.

Edward Septimus, MD does not have relevant financial relationships with commercial interests.

  • Dr. Septimus does not discuss off-label uses of any products.

George Karam, MD has relevant financial relationships with the following commercial interests:

  • Advisory Board: Merck & Co., Inc.
  • Consultant: Merck & Co., Inc., Shionogi Inc.
  • Dr. Karam does not discuss off-label uses of any products.

Marin Kollef, MD has relevant financial relationships with the following commercial interests:

  • Advisory Board: Merck & Co., Inc., Shionogi Inc., Aridis
  • Dr. Kollef does not discuss off-label uses of any products.

Melissa Johnson, PharmD has relevant financial relationships with commercial interests:

  • Consultant: Shionogi Inc., Cidara, Paratek, Health & Wellness Partners
  • Research Support: Merck & Co., Inc., Scynexis
  • Dr. Johnson does not discuss off-label uses of any products. 

No (other) speakers, authors, planners or content reviewers have any relevant financial relationships to disclose.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

There is no fee to participate in this activity.

Hardware/Software Requirements
Microsoft Internet Explorer, Mozilla Firefox, Apple Safari or Google Chrome with the QuickTime Plug-in
Note: Please disable any “pop-up blocker” features.

Adobe® Reader version 7 or above to view PDF files (If you do not have Adobe® Reader, you can download it for free from
Adobe Flash Player version 10 or above to view multimedia content (If you do
not have Adobe Flash Player, you can download it for free from

Connection Speed
Cable, DSL, or better of at least 300 kbps

System Check
Please e-mail any questions or concerns to

Copyright Statement
Copyright © 2020 Vemco MedEd. All Rights Reserved. Permission for accreditation use granted to Center for Independent Healthcare Education.

Privacy Policy

Joint Providership
This activity is jointly provided by Center for Independent Healthcare Education and Vemco MedEd.

Commercial Support

This activity is supported by an educational grant from  Merck & Co., Inc.

By clicking below, I acknowledge that I have read the entire CME/CPE information.